Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of “Buy” from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus recommendation of “Buy” from the sixteen ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have given a buy rating and three have given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $32.6364.

A number of research firms have weighed in on DNLI. Morgan Stanley cut their price objective on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Monday, August 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, October 8th. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a research note on Monday, November 17th. Finally, JPMorgan Chase & Co. boosted their target price on Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th.

Denali Therapeutics Stock Up 1.5%

DNLI stock opened at $19.69 on Monday. The company has a market capitalization of $2.89 billion, a P/E ratio of -6.76 and a beta of 1.11. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $26.18. The firm’s fifty day simple moving average is $16.13 and its 200-day simple moving average is $14.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.02. Denali Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.63) EPS. As a group, equities research analysts forecast that Denali Therapeutics will post -2.71 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently modified their holdings of the business. Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the second quarter worth $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the third quarter worth $29,000. State of Wyoming purchased a new position in Denali Therapeutics in the second quarter valued at $29,000. Caitong International Asset Management Co. Ltd grew its stake in Denali Therapeutics by 277.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock worth $29,000 after purchasing an additional 1,551 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Denali Therapeutics during the 1st quarter worth about $41,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.